Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Fig. 3

a–d Cumulative incidence of breast cancer (BC)-related events (BCFi) in different breast cancer subtypes. The panel illustrates the result of different levels of TILs in a all patients, and patients with the following breast cancer subtypes; b ER+/HER2−; c HER2+; and d TNBC. The patients were allocated to no adjuvant systemic treatment and TILs were categorised as low: < 10%, intermediate: 10–49% and high: ≥ 50%. Abbreviations: BCFi breast cancer-free interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, TILs tumour-infiltrating lymphocytes, TNBC triple-negative breast cancer

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us